Real-World Safety and Effectiveness of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis

Pulmonary fibrosis: clinical and trial experiences

Chair(s): Claudia Valenzuela, Katarzyna B. Lewandowska

Session type: Poster session

Arata Azuma

EVENTS HOME

Poster
Abstract

Previous presentation

Next presentation

Session content

Effects of nintedanib on circulating biomarkers in patients with progressive pulmonary fibrosis: subgroups by fibrotic pattern on HRCT

Toby M Maher

Poster

Abstract

Interobserver variability of the ATS/ERS/JRS/ALAT diagnostic CT criteria for idiopathic pulmonary fibrosis: a systematic review and meta-analysis

Krit Dwivedi

Poster

Abstract

High antinuclear antibody titer is associated with increased mortality risk in patients with idiopathic pulmonary fibrosis

Shimon Izhakian

Poster

Abstract

Progressive pulmonary fibrosis in patients with chronic hypersensitivity pneumonitis (cHP): a single center experience.

Julia Walscher

Poster

Abstract

Autoantibody positivity (AAb+) in idiopathic pulmonary fibrosis (IPF): outcomes from the Pulmonary Fibrosis Foundation Patient Registry (PFF-PR)

Tejaswini Kulkarni

Poster

Abstract

Interstitial lung diseases in Israel

Tzlil Hershko

Poster

Abstract

Comparison of the diagnostic criteria for progressive pulmonary fibrosis in connective tissue disease related interstitial lung disease

Hyunwoo Kim

Poster

Abstract

Antifibrotic treatment in patients with Idiopathic pulmonary fibrosis (IPF): Real life data from a Swedish registry

Lisa Carlson

Poster

Abstract

Real-World Safety and Effectiveness of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis

Arata Azuma

Poster

Abstract

Real-world study evaluating anti-fibrotic therapy on survival in idiopathic pulmonary fibrosis

Lucy Robertson

Poster

Abstract

Continued nintedanib treatment in patients with progressive pulmonary fibrosis: data from INBUILD-ON

Wim A. Wuyts

Poster

Abstract

Impact of antifibrotic therapy on lung cancer incidence and mortality in patients with idiopathic pulmonary fibrosis

Yong Suk Jo

Poster

Abstract

Five-year follow up analysis of Japanese ILD registry

Kazuya Tsubouchi

Poster

Abstract

Comparison of antifibrotic availability for patients on the BTS IPF Registry using existing and new prescribing criteria

Jennifer Naftel

Poster

Abstract

Adverse Effects of Nintedanib A Portent of Gender Inequality?

Dominic Sykes

Poster

Abstract

Characteristics of patients with progressive fibrosing ILDs in the ILD-PRO Registry

Leonard Lobo

Poster

Abstract

Idiopathic pulmonary fibrosis treated by Nintedanib: evaluation of safety even in patients treated with anticoagulants

Barbara Ruaro

Poster

Abstract

Nocebo effect of nintedanib on gastrointestinal (GI) adverse events (AEs) in patients with interstitial lung diseases (ILDs)

Oliver Distler

Poster

Abstract

Meta-analysis of effect of nintedanib on mortality in subjects with idiopathic pulmonary fibrosis (IPF) and other forms of progressive pulmonary fibrosis (PPF)

Wim A. Wuyts

Poster

Abstract

Clinical and prognostic significance of p-ANCA antibodies positivity in Idiopathic Pulmonary Fibrosis

Giuseppe Muscato

Poster

Abstract

The ERS International Congress 2023, Milan

#{title}